Alcon to Acquire LumiThera and its Dry AMD Light Therapy Device

GENEVA—Alcon (SIX/NYSE: ALC), a global leader in eyecare, has announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD). According to the announcement, LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to the baseline for people living with early to intermediate dry AMD. Alcon said the acquisition aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases.